After the early success of Immune Checkpoint Inhibitors, T-cell immunotherapy has emerged as another innovative and potent arm of the immuno-oncology market. Characterised by key features such as target specificity, adaptability and memory, T-cells have been effectively used as tools to mediate an immune response.
According to a recent report published by Roots Analysis, there are close to 180 therapies across various phases of development. The study offers a comprehensive analysis of the future outlook of CAR-T, TCR and TIL therapies. Apurva Bhardwaj, the principal analyst, stated, “The likely growth is supported by a robust and opportunistic pipeline targeting various indications. The T-cell therapy market is expected to make a huge leap over the coming decade and be worth USD 30 billion by 2030. Innovative research, lucrative rounds of VC funding, discovery of several novel targets and encouraging clinical trial results have emerged as the key drivers of this market.”